Follistatin (344/315)

Common side effects:

• Injection site irritation and redness
• Mild joint pain during initial growth phases
• Temporary water retention
• Increased appetite and lethargy

Rare or serious side effects:

• Unregulated tissue growth
• Potential cardiovascular strain due to rapid mass gain
• Alterations in reproductive hormones including FSH suppression
• Ligament and tendon strain from disproportionate muscle strength

Myostatin and Activin A Neutralization forms the primary mechanism of action for the Follistatin (344/315) peptide. It functions as a binding protein that attaches directly to myostatin (GDF-8) and activin A, preventing them from binding to their cellular receptors. Because myostatin normally acts as a negative regulator of skeletal muscle growth, its neutralization removes the biological brakes on muscle development. Isoform Specificity dictates the distinct pharmacokinetic properties of Follistatin 344 and 315. Follistatin 344 is a precursor that cleaves into the tissue-bound Follistatin 315 isoform, which exhibits a strong affinity for heparan sulfate proteoglycans on cell surfaces (Datta-Mannan A et al., 2013). This localized binding ensures that the peptide exerts its potent anabolic effects directly within skeletal muscle tissue while minimizing systemic circulation.

Initial Discovery of follistatin occurred in the late 1980s when researchers isolated it from porcine follicular fluid, identifying it as a novel polypeptide that inhibits the release of follicle-stimulating hormone (Esch FS et al., 1987). Subsequent genetic sequencing, including the isolation of bovine follistatin cDNA, revealed its broader role as a regulatory glycoprotein across multiple species (Saleh M et al., 1994). Regulatory Status remains strictly confined to laboratory and preclinical settings, as the FDA has not approved Follistatin (344/315) for human therapeutic use. Due to its potent muscle-building properties, it has gained attention in performance-enhancing circles, prompting the development of specific assays to detect black market follistatin 344 in anti-doping efforts (Reichel C et al., 2019). Currently, it is legally available only as a research-only compound for in vitro and animal studies.